R Wendel Naumann1, Charles A Leath2. 1. Levine Cancer Institute, Atrium Health, Charlotte, North Carolina. 2. University of Alabama at Birmingham, Birmingham, Alabama, USA.
Abstract
PURPOSE OF REVIEW: Novel therapies are needed for the treatment of recurrent cervical cancer. The best chemotherapy regimen to date has a response rate of 48% with an overall survival of 17 months, with limited options for second-line chemotherapy. Immunotherapy can induce a strong immune response in cervical cancer due to retained viral antigens and is reviewed in this article. RECENT FINDINGS: Current clinical trials include treatment with Listeria that elicits an immune response against the E7 oncoprotein and active vaccines against the E7 oncoprotein. Although the response rates to programmed cell death 1 (PD-1) inhibition alone have been modest, the landmark survival reported in these trials suggests the activity of these agents may not be measured by RECIST criteria. The KEYNOTE-158 trial has led to the approval of pembrolizumab in recurrent programmed cell death ligand 1 (PD-L1) positive cervical cancer. Combinations of programmed cell death 1 and anticytotoxic T-lymphocyte-associated protein 4 inhibitors (CTLA4) inhibitors have shown promising and durable activity. There is active research with new combinations of checkpoint inhibitors, as well as combinations of these drugs with chemotherapy and radiation, and other novel approaches. SUMMARY: Immune therapy has broad activity in cervical cancer. Responses to immunotherapy can be dramatic and durable. Continued work to find the optimal combination and setting for immunotherapy is ongoing.
PURPOSE OF REVIEW: Novel therapies are needed for the treatment of recurrent cervical cancer. The best chemotherapy regimen to date has a response rate of 48% with an overall survival of 17 months, with limited options for second-line chemotherapy. Immunotherapy can induce a strong immune response in cervical cancer due to retained viral antigens and is reviewed in this article. RECENT FINDINGS: Current clinical trials include treatment with Listeria that elicits an immune response against the E7 oncoprotein and active vaccines against the E7 oncoprotein. Although the response rates to programmed cell death 1 (PD-1) inhibition alone have been modest, the landmark survival reported in these trials suggests the activity of these agents may not be measured by RECIST criteria. The KEYNOTE-158 trial has led to the approval of pembrolizumab in recurrent programmed cell death ligand 1 (PD-L1) positive cervical cancer. Combinations of programmed cell death 1 and anticytotoxic T-lymphocyte-associated protein 4 inhibitors (CTLA4) inhibitors have shown promising and durable activity. There is active research with new combinations of checkpoint inhibitors, as well as combinations of these drugs with chemotherapy and radiation, and other novel approaches. SUMMARY: Immune therapy has broad activity in cervical cancer. Responses to immunotherapy can be dramatic and durable. Continued work to find the optimal combination and setting for immunotherapy is ongoing.
Authors: Krishnansu S Tewari; James J Java; Troy A Gatcliffe; Michael A Bookman; Bradley J Monk Journal: Gynecol Oncol Date: 2014-03-20 Impact factor: 5.482
Authors: Diane M Da Silva; Joseph G Skeate; Elena Chavez-Juan; Kim P Lühen; Jiun-Ming Wu; Chia-Mao Wu; W Martin Kast; KinKai Hwang Journal: Vaccine Date: 2019-04-19 Impact factor: 3.641
Authors: Ronald D Alvarez; Warner K Huh; Sejong Bae; Lawrence S Lamb; Michael G Conner; Jean Boyer; Chenguang Wang; Chien-Fu Hung; Elizabeth Sauter; Mihaela Paradis; Emily A Adams; Shirley Hester; Bradford E Jackson; T C Wu; Cornelia L Trimble Journal: Gynecol Oncol Date: 2015-11-23 Impact factor: 5.482
Authors: Warner K Huh; Elmar A Joura; Anna R Giuliano; Ole-Erik Iversen; Rosires Pereira de Andrade; Kevin A Ault; Deborah Bartholomew; Ramon M Cestero; Edison N Fedrizzi; Angelica L Hirschberg; Marie-Hélène Mayrand; Angela Maria Ruiz-Sternberg; Jack T Stapleton; Dorothy J Wiley; Alex Ferenczy; Robert Kurman; Brigitte M Ronnett; Mark H Stoler; Jack Cuzick; Suzanne M Garland; Susanne K Kjaer; Oliver M Bautista; Richard Haupt; Erin Moeller; Michael Ritter; Christine C Roberts; Christine Shields; Alain Luxembourg Journal: Lancet Date: 2017-09-05 Impact factor: 79.321
Authors: J M Herter; M Kiljan; S Kunze; M Reinscheid; O Ibruli; J Cai; L Niu; I Heßelmann; M Trommer; G S Herter-Sprie; C Köhler; S Marnitz Journal: Strahlenther Onkol Date: 2022-10-17 Impact factor: 4.033